The Mark Foundation for Cancer Research: Funding, Team & Investors | Startup Intros

Loading organizations...

The Mark Foundation for Cancer Research: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 1, 2024	Accent Therapeutics	$75.0M Series C	—	Atlas Venture, F-Prime Capital Partners, Leaps by Bayer, Nextech Invest, The Column Group, AbbVie Ventures, Bristol Myers Squibb, Droia Ventures, EcoR1 Capital, Google Ventures, Johnson & Johnson Innovation, Naveen Krishnan, Mirae Asset Venture Investment, Timefolio Capital
Jul 1, 2022	Vicinitas Therapeutics	$65.0M Series A	Deerfield Management, Jorge Conde	5AM Ventures, Andreessen Horowitz, Maverick Capital, Northpond Ventures, Vivo Capital, Berkeley Catalyst Fund, George Golumbeski, Google Ventures
Aug 1, 2021	Immunitas Therapeutics	$58.0M Series B	Agent Capital	Alta Partners, Cofounders Capital, Domain Associates, Leaps by Bayer, Longwood Fund, Novartis Venture Fund, Providence Ventures, RA Capital, Section 32, Netalie Nadivi, 120 Capital, Alexandria Venture Investments, Evotec, Brian Halak, Mirae Asset, M Ventures, Novartis, NS Investment, Ono Venture Investment, Solasta Ventures, The Leukemia & Lymphoma Society
May 1, 2021	Interius BioTherapeutics	$76.0M Series A	Cormorant Asset Management, Tomas Kiselak	Agent Capital, Bain Capital Life Sciences, Cofounders Capital, American Cancer Society, BrightEdge, Knollwood Investment Advisory, Logos Capital, Longwood Fund, Osage University Partners, Quin Capital, RA Capital Management, Lonnie Moulder Jr, University of Pennsylvania
Apr 1, 2021	C2i Genomics	$100.0M Series B	Casdin Capital	Album VC, NFX, Alexandria Venture Investments, Driehaus Capital Management, Duquesne Family Office, Gordon Asset Management, iGlobe Partners, LionBird, NFX, Section 32, Silver Lake
Jun 1, 2020	C2i Genomics	$12.0M Series A	Casdin Capital	Album VC, NFX, James Currier
Apr 1, 2020	Accent Therapeutics	$63.0M Series B	Oleg Nodelman	Atlas Venture, F-Prime Capital Partners, Nextech Invest, The Column Group, AbbVie Ventures, Droia Ventures, Google Ventures, NS Investment